Inaugural CCF Stakeholder’s Meeting, February 27-28, 2014
- In collaboration with Huntsman Cancer Institute, the University of Utah, the Bili Project, and Target Cancer
- 56 physicians and researchers attended from 27 US and international cancer centers
- 9 working groups were formed to work cross-institutionally on basic, translational and clinical outcomes
- Sessions focused on the latest updates, research, current data and treatment options for cholangiocarcinoma
Thanks to all the investigators for their contributions and commitment. Without everybody’s genuine efforts, it would not have been possible to come up with that many potentially fundable projects in that little period of timeGhassan K. Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center,
2014 Inaugural CCF Stakeholders Meeting Chair
First deliverable from 2014 Stakeholder’s Meeting!
Biliary Emergency Information Card
In an effort to educate patients and physicians about potentially fatal risks of ascending cholangitis, CCF has created the Biliary Emergency Information Card. Patients can quickly and easily complete a free, online form that populates the Biliary Emergency Information Card with patient information for their specific cholangiocarcinoma treatment and their health care providers’ contact information. The patients can print and fold the card so it is accessible at all times. Instructions on the card also include specific emergency treatment guidelines. Medical personnel can scan a QR code or visit the Foundation website for additional instructions on symptoms, signs, labs, workup, treatment and follow-up for the patient.
Genetic Models of Intrahepatic Cholangiocarcinoma
Nabeel Bardeesy, PhD
Dana-Farber/Harvard Cancer Center
All cancers have genetic mutations that cause cells to grow abnormally. Patients with cholangiocarcinoma have different combinations of such mutations that result in distinct subtypes of the disease and may have their own specific responses to therapy. It is therefore important to develop relevant model systems to understand how these different mutations affect the biology of cholangiocarcinoma and the response to treatment. The most common mutations in cholangiocinoma occur in two closely related genes called Isocitrate Dehydrogenase 1 and 2 (IDH1, IDH2). The Bardeesy lab presented recent findings regarding how IDH mutations cause cholangiocarcinoma. In particular, they found that mutant IDH prevents liver stem cells from responding to normal signals to stop growing and maturing into normal liver cells. They also developed genetically engineered mouse models that enable the testing of new treatments for IDH mutant cholangiocarcinoma.
This work will be published in the upcoming 1-2 months and the findings will subsequently be made available on this website.
Immune Response to Cholangiocarcinoma
Cristina R. Ferrone, MD
Massachusetts General Hospital Cancer Center
Molecular Profiling of Cholangiocarcinoma
Milind Javle, MD
Department of GI Medical Oncology
Liver Transplantation for Hilar Cholangiocarcinoma
Robin D. Kim, MD
Executive Medical Director, Transplant Service Line Director, Hepatobiliary Cancer Program
Huntsman Cancer Institute and the University of Utah
Locoregional Therapies for Cholangiocarcinoma
Armeen Mahvash, MD
CEACAM6 as a Biomarker for Cholangiocarcinoma
Virginia Mason Medical Center
Flavio G. Rocha, MD, FACS
CEACAM6 as a biomarker for cholangiocarcinoma
Virginia Mason Medical Center
Flavio G. Rocha, MD, FACS
My research focuses on the identification and validation of protein biomarkers for the diagnosis and prognosis of bile duct cancer. Previous studies have demonstrated that CEACAM6, a cell surface glycoprotein member of the carcinoembryonic antigen family, is overexpressed in several gastrointestinal cancers. In addition, proteomic studies have shown that CEACAM6 is present in the bile of patients with malignant biliary strictures.
Using a tissue microarray assembled from archived biliary cancer specimens, CEACAM6 was found in half of extrahepatic cholangiocarcinomas (ECC) and a minority of intrahepatic cholangiocarcinomas (ICC) by immunohistochemistry. However, patients with ICC that expressed CEACAM6 had a significantly worse disease-specific survival despite curative resection.
Bile was collected from patients undergoing resection of both benign and malignant biliary disease. Biliary CEACAM6 levels were measured by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blot. Patients with cholangiocarcinoma had significantly higher levels of CEACAM6 in their bile. Receiver operator curves demonstrated a high sensitivity and specificity of CEACAM6 level for the diagnosis of ECC.
Current studies include the evaluation of CEACAM6 expression in a prospective clinical trial of hepatic arterial chemotherapy for unresectable ICC to determine prognostic capability and measurement of CEACAM6 levels in the serum of cholangiocarcinoma patients for predictive purposes.
Update on the International Hepatobiliary Neoplasia Registry and the Proposed Genome Wide Associations Study of Cholangiocarcinoma
Lewis Roberts, MB, ChB, PhD
Thanks a lot, for a superb event. It’s hard to believe your organization is still so young, and you have already achieved so much. I have been to other such events before, but the enthusiasm in that room was very palpable.Milind Javle, MD - MD Anderson
2014 Cholangiocarcinoma Foundation Stakeholders Meeting Working Group Summaries
Thanks very much for the outstanding stakeholder meeting you organized last week. It was great to meet the scientists and advocates and I look forward to seeing results from this meeting over the ensuing months and years.Lewis Roberts, MD - Mayo Clinic
The conference was extremely well organized, coordinated and planned. The conference members you put together from across basic research, translation and clinical capabilities creates a complete eco-system to impact this field. . . the event will enable many collaborative discussions to advance the goals of the Foundation.Taher Abbasi, Cellworks Group